Novogene Co., Ltd. Class A 688315
SSE · China · Health Services
CNY 19.77+0.87 (+4.60%)
Market closed· · CNY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · CNY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
On June 8, 2026, the U.S. Department of Defense (DOD) erroneously designated Novogene Co., Ltd. on its Section 1260H list under the National Defense Authorization Act for Fiscal Year 2021. This designation is factually incorrect.
TMO teams up with PRECISE on a major proteomics study, expanding its role in large biobank projects and precision medicine initiatives.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.